Assenagon Asset Management S.A. Purchases New Position in Soleno Therapeutics, Inc. $SLNO

Assenagon Asset Management S.A. acquired a new position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 384,166 shares of the company’s stock, valued at approximately $17,787,000. Assenagon Asset Management S.A. owned approximately 0.72% of Soleno Therapeutics as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of SLNO. Raymond James Financial Inc. purchased a new stake in shares of Soleno Therapeutics in the 2nd quarter worth $25,000. Danske Bank A S bought a new position in shares of Soleno Therapeutics during the 3rd quarter worth $27,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Soleno Therapeutics during the third quarter valued at $37,000. Quarry LP purchased a new position in shares of Soleno Therapeutics during the third quarter valued at $47,000. Finally, Quantbot Technologies LP bought a new stake in shares of Soleno Therapeutics in the third quarter valued at about $67,000. 97.42% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on SLNO. HC Wainwright lowered their price objective on shares of Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research note on Wednesday, March 4th. Wall Street Zen lowered shares of Soleno Therapeutics from a “buy” rating to a “hold” rating in a report on Sunday, March 22nd. Zacks Research cut shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 3rd. Robert W. Baird set a $107.00 price target on shares of Soleno Therapeutics in a research report on Tuesday, January 13th. Finally, Wells Fargo & Company dropped their price objective on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $102.60.

Soleno Therapeutics Price Performance

Shares of SLNO stock opened at $31.86 on Friday. The stock’s 50-day moving average is $38.77 and its 200 day moving average is $48.95. Soleno Therapeutics, Inc. has a 1-year low of $30.11 and a 1-year high of $90.32. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.80 and a quick ratio of 5.55. The company has a market cap of $1.64 billion, a P/E ratio of 138.53 and a beta of -3.16.

Soleno Therapeutics (NASDAQ:SLNO) last announced its earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The firm had revenue of $91.73 million during the quarter, compared to the consensus estimate of $88.55 million. Research analysts predict that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current fiscal year.

Soleno Therapeutics News Roundup

Here are the key news stories impacting Soleno Therapeutics this week:

• Negative Sentiment: Hagens Berman announces a securities class action alleging losses tied to Soleno’s DCCR disclosures. Read More.
• Negative Sentiment: Rosen Law Firm reminds investors of May 5, 2026 lead-plaintiff deadline and solicits clients. Read More.
• Negative Sentiment: Kessler Topaz issues investor alert for purchasers during the Class Period. Read More.
• Negative Sentiment: Bernstein Liebhard announces a shareholder class action filing and solicits participation. Read More.
• Negative Sentiment: Pomerantz LLP issues investor alert and contact information for potentially affected shareholders. Read More.
• Negative Sentiment: Portnoy Law Firm announces a class action covering purchases from March 6–Nov 4, 2025 and the May 5 deadline. Read More.
• Negative Sentiment: SueWallSt alerts investors and highlights alleged misrepresentation of DCCR safety timeline. Read More.
• Negative Sentiment: Robbins Geller files a class action and invites investors to seek lead-plaintiff status. Read More.
• Negative Sentiment: Glancy Prongay Wolke & Rotter notifies investors of opportunity to lead the securities fraud lawsuit. Read More.
• Negative Sentiment: Levi & Korsinsky alleges possible sham clinical-trial conduct in their investor alert. Read More.
• Negative Sentiment: Faruqi & Faruqi reminds investors of the May 5, 2026 class action deadline. Read More.
• Negative Sentiment: ClaimsFiler and other services remind large-loss investors about the lead-plaintiff deadline. Read More.
• Negative Sentiment: Kaplan Fox, Kahn Swick & Foti and other firms issue similar alerts and notices to investors. Read More. Read More.

Soleno Therapeutics Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.